Valeant On Track To File Retigabine For Epilepsy In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending approval, the first-in-class neuronal potassium channel opener would launch in 2009.
You may also be interested in...
Valeant Seeking Return To Growth With New Chief Executive
Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.
Valeant Seeking Return To Growth With New Chief Executive
Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.
Eisai’s Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson’s Disease
Japanese drug maker says it now plans to file the AMPA receptor antagonist in fiscal fourth quarter 2008, not fiscal 2007.